Recently our research group demonstrated in collaboration with the group of Prof. Bart Staels (Pasteur Institute Lille) that upon combining glucocorticoids with PPAR agonists, an additive anti-inflammatory effect is established, surprisingly in the absence of diabetogenic side effects (Bougarne et al., Proc. Natl. Acad. Sci., 2009). The current research proposal will focus on determining the underlying molecular mechanisms allowing to explain the cross-talk between PPAR and GR.